Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | GPR39 | O43194 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15720210 | 0.92 | LMNA (0.43) | PDE4ALMNAKCNH3IDH1KMT2A | |
| SCHEMBL20511448 | 0.84 | PDE4A (0.42) | PDE4ALMNAIDH1PTGS2MEN1 | |
| SCHEMBL15720214 | 0.82 | PDE4A (0.63) | PDE4ALMNARAB9A | |
| SCHEMBL15739148 | 0.80 | LMNA (0.58) | PDE4ALMNAKCNH3KMT2AGAA | |
| SCHEMBL20814491 | 0.79 | LMNA (0.50) | PDE4ALMNAKCNH3IDH1KMT2A | |
| SCHEMBL17158320 | 0.79 | KCNH3 (0.33) | KCNH3IDH1PTGS2MEN1KMT2A | |
| SCHEMBL8054361 | 0.79 | IDH1 (0.46) | KCNH3IDH1PTGS2MEN1KMT2A | |
| SCHEMBL15720782 | 0.78 | KCNH3 (0.41) | KCNH3IDH1VCPGPR39 | |
| Hydrochloric Acid SCHEMBL17158291 | 0.78 | KCNH3 (0.35) | KCNH3IDH1PTGS2MEN1KMT2A | |
| SCHEMBL15720742 | 0.78 | PDE4A (0.56) | PDE4ALMNAKCNH3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2920155-A2 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | Galleon Pharmaceuticals, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078575-A2 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | MTNR1B, TNNC1, PER2 | PDE4A 27/4885LMNA 1297/4885KCNH3 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.